Detalhe da pesquisa
1.
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
J Hepatol
; 79(5): 1110-1120, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37517454
2.
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet
; 394(10215): 2184-2196, 2019 12 14.
Artigo
Inglês
| MEDLINE | ID: mdl-31813633
3.
Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection.
Therap Adv Gastroenterol
; 17: 17562848241239547, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38529070
4.
Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTATM) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection.
Open Forum Infect Dis
; 10(5): ofad171, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-37256213
5.
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Drugs
; 82(15): 1527-1538, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-36287379
6.
Diverticular disease-associated segmental colitis.
Clin Gastroenterol Hepatol
; 5(1): 27-31, 2007 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-17234553
7.
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Drugs
; 82(15): 1539, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-36342618